Low recruitment ratio

It is a multicenter, national, randomized 1:1 ratio, controlled, parallel, open study.

Patients with severe ARDS-CoVid19 will be included in the trial within the first 24 hours.

Patients will be randomized to one of the treatment groups:

• SEV group: 25 patients with Sevoflurane sedation by inhalation, starting at 6 ml/h and changing every 15 minutes until an adequate level of sedation is achieved (BIS 40-50)
• PRO group: 25 patients standard sedation with intravenous propofol, starting with 2 mg/kg/h and changing every 15 minutes until an adequate level of sedation is achieved ( BIS 40-50)

Inclusion Criteria:

• Age 18 years or more.
• Diagnosis of Acute Respiratory Distress Syndrome caused by COVID19 infection.
• Signature of Patient's Consent or Verbal Consent of Legal Representative

Exclusion Criteria:

• Intracranial hypertension
• Hypersensitivity to the active ingredient (propofol or sevoflurane) or to any of the excipients
• Current volume < 250ml
• History of malignant hyperthermia
• Liver failure
• Neutropenia (<0.5x109)
• Pregnant or lactating women
• Have received chemotherapy in the last month since their inclusion in the study